He H, Zhang J P, Wei Z J, Lu Y, Zhao Y L, Sun R J
Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang 065300, China.
Zhonghua Xue Ye Xue Za Zhi. 2024 Nov 14;45(11):1016-1021. doi: 10.3760/cma.j.cn121090-20240906-00339.
This study aimed to investigate the role of human herpesvirus (HHV) infection in refractory intestinal graft-versus-host disease (GI-GVHD) after hematopoietic stem cell transplantation (HSCT) and its diagnosis and treatment. This study retrospectively analyzed patients presenting with refractory GI-GVHD after allogeneic HSCT (allo-HSCT) with concomitant colonoscopy and mucosal biopsy at Lu Daopei Hospital, Yanda, Hebei, from March 2022 to July 2024. Human herpesvirus 6 (HHV6), HHV7, cytomegalovirus (CMV), and Epstein-Barr virus (EBV) detection with the RQ-PCR method. The intestinal mucosa was pathologically assessed and immunohistochemistry was utilized to detect the CMV early antigen, CMV late antigen, and EBV by in situ hybridization. This study included 42 patients, consisting of 25 males and 17 females with a median age of 26 (1-59) years. All were histopathologically diagnosed as GI-GVHD. Among them, 34 (81.0%) cases had combined viral enteritis, with 52.4% positive for EBV, 38.1% positive for HHV6, 26.2% positive for CMV, and 14.3% positive for HHV7. Further, 17 (40.5%) cases had mixed viral infections, including 5 EBV+ HHV6, 3 CMV+HHV6, 3 CMV+EBV, 2 CMV+EBV+HHV6, 2 EBV+HHV6+HHV7, 1 EBV+HHV7, and 1 HHV6 + HHV7 cases. Furthermore, 17 (40.5%) had a single viral infection, including 9 EBV, 3 CMV, 3 HHV6, and 2 HHV7 cases. Moreover, 17 (40.5%) patients exhibited a positive histopathological viral test, including 7 (16.6%) CMV-positive and 12 (28.5%) EBV-positive cases. The same positive virus was detected in the feces of all 34 patients with positive tissue homogenate virus, and the positive rate of the same virus in the blood was 17.6%. Tissue homogenized virus testing was utilized as the diagnostic criterion for enterocolitis: blood tests for CMV, EBV, HHV6, and HHV7 demonstrated a sensitivity of 45.4%, 4.5%, 6.3%, and 0%, and specificity of 90.3%, 95%, 100%, and 110%, respectively. Additionally, fecal tests for CMV, EBV, HHV6, and HHV7 demonstrated a sensitivity and specificity of 100%. Treatment based on etiology caused ORR and CR rates for diarrhea of 76.1% (32/42) and 66.6% (28/42), respectively. The median follow-up of 42 patients was 13 (1 - 49) months, and 28 patients survived, with an expected 2-year survival rate of 61.9%. In addition to GVHD itself, intestinal human herpesvirus infection is one of the reasons for the refractory nature of GI-GVHD. Viral testing in blood and tissues reveals significant segregation, and the possibility of comorbid viral enteritis cannot be excluded even if a patient with GI-GVHD tests negative for blood viruses.
本研究旨在探讨人类疱疹病毒(HHV)感染在造血干细胞移植(HSCT)后难治性肠道移植物抗宿主病(GI-GVHD)中的作用及其诊断和治疗。本研究回顾性分析了2022年3月至2024年7月在河北燕达陆道培医院接受异基因HSCT(allo-HSCT)后出现难治性GI-GVHD并同时进行结肠镜检查和黏膜活检的患者。采用RQ-PCR方法检测人类疱疹病毒6型(HHV6)、HHV7、巨细胞病毒(CMV)和爱泼斯坦-巴尔病毒(EBV)。对肠道黏膜进行病理评估,并利用免疫组化通过原位杂交检测CMV早期抗原、CMV晚期抗原和EBV。本研究纳入42例患者,其中男性25例,女性17例,中位年龄为26(1-59)岁。所有患者均经组织病理学诊断为GI-GVHD。其中,34例(81.0%)合并病毒性肠炎,EBV阳性率为52.4%,HHV6阳性率为38.1%,CMV阳性率为26.2%,HHV7阳性率为14.3%。此外,17例(40.5%)为混合病毒感染,包括5例EBV+HHV6、3例CMV+HHV6、3例CMV+EBV、2例CMV+EBV+HHV6、2例EBV+HHV6+HHV7、1例EBV+HHV7和1例HHV6+HHV7。此外,17例(40.5%)为单一病毒感染,包括9例EBV、3例CMV、3例HHV6和